CT-155 (Boehringer Ingelheim and Click Therapeutics), an investigational prescription digital therapeutic, was both safe and effective in reducing negative symptoms of schizophrenia in a new phase 3 ...
A yearslong collaboration between Click Therapeutics and drugmaker Boehringer Ingelheim exploring the potential of digital apps in schizophrenia therapy will now be put to the test in the clinic. The ...
Boehringer Ingelheim has amended its partnership with Click Therapeutics on a digital therapeutic (DTx) for schizophrenia, transferring commercial rights to the programme to the digital health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results